Curaleaf is making a major play in Virginia’s cannabis landscape, striking a $110 million deal to acquire the Central Virginia medical marijuana operations of The Cannabist Company. The agreement hands Curaleaf control of five existing dispensaries, another one on the way, and more than 80,000 square feet of cultivation and production space in the Richmond region — essentially giving the company the keys to the city’s medical cannabis supply.
The purchase comes with a tiered payment structure, starting with $80 million upfront, followed by $20 million in deferred cash and a $10 million promissory note. If the deal falls through due to competing offers or lack of internal approvals, Curaleaf is set to walk away with a tidy breakup fee, proving that even in the cannabis world, there’s always a prenup.
The acquisition is expected to close in early 2026, but for now the agreement sits in a short “go-shop” window that allows The Cannabist Company to solicit better offers. Whether any buyers swoop in remains to be seen, but the clock is ticking.
This sale comes as Virginia prepares to open the door to adult-use cannabis retail — a shift that has sparked renewed interest in the state’s limited number of vertically integrated medical licenses. As the regulatory baton has now officially passed to the Virginia Cannabis Control Authority, the agency acknowledges the sale with a shrug: under current rules, companies simply have to notify the state when a license changes hands. That’s it. No approval needed.
Industry watchers say the deal reflects the growing consolidation of Virginia’s cannabis industry, where multistate operators like Curaleaf have the capital to scale quickly. Advocates, meanwhile, hope the shift will translate into better prices and more accessible products for patients.
The Cannabist Company has been steadily slimming down its national footprint after a challenging financial stretch, selling off dispensaries and cultivation facilities in several states. The Richmond sale is its latest move to streamline operations and refocus resources.
For now, Curaleaf appears poised to expand its footprint in one of the country’s most closely watched emerging cannabis markets — and Richmond’s medical marijuana scene may soon have a new boss in town.
Dabbin-Dad Newsroom
